VERAXA Biotech AG, a portfolio company of Xlife Sciences AG (SIX: XLS), has secured $27.5 million in senior secured convertible note financing from High Trail Capital LP and entered into a share purchase agreement providing access to up to $50 million in equity financing with Lincoln Park Capital Fund LLC. The financing arrangements are intended to bolster VERAXA's financial position ahead of its planned business combination with Voyager Acquisition Corp. and anticipated listing on the Nasdaq Capital Market.
The High Trail Capital financing includes a 15-month senior secured convertible note and warrants exercisable over four years at an initial exercise price of $11.50 per share. The equity line with Lincoln Park Capital provides VERAXA with discretionary access to capital over a 24-month period without warrants or participation rights. The company stated that the combined financing structure supports continued development of its antibody-based therapeutic pipeline, including proprietary BiTAC formats and antibody-drug conjugates.
This financial injection comes at a critical time for VERAXA as it prepares for its public market debut. The funds will enable the company to advance its drug discovery and development programs, which are rooted in scientific discoveries from the European Molecular Biology Laboratory (EMBL), a world-leading institute for life science research. VERAXA focuses on creating antibody drug conjugates and novel BiTAC antibody formats, aiming to accelerate these therapies into and through clinical development.
The significance of this announcement extends beyond VERAXA. It highlights the continued interest of specialized investment firms in biotechnology companies with promising pipelines. High Trail Capital and Lincoln Park Capital's involvement signals confidence in VERAXA's technology and its potential to address unmet medical needs. For the industry, this financing model—combining secured debt with an equity line—provides a blueprint for other biotech firms seeking to fund operations while preparing for a public listing.
For readers and investors, the news underscores the importance of VERAXA's upcoming business combination with Voyager Acquisition Corp., which will result in a Nasdaq listing. This event could provide liquidity and further growth capital, potentially accelerating the development of therapies that target cancer and other diseases. The success of VERAXA's pipeline could impact patients by offering new treatment options and influence the broader biotech sector by validating the BiTAC platform.
More information about VERAXA Biotech AG can be found at https://www.veraxa.com/. Details about Xlife Sciences AG are available at https://www.xlifesciences.ch. The full press release is accessible at https://ibn.fm/oxUOU.
